hPSC-Derived Universal NK Cells With CAR Targeting and Memory Persistence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing NK cells from human pluripotent stem cells face challenges such as non-standardized protocols, high costs, long derivation periods, and limited immunological memory, hindering their application in cancer therapy.
Innovation Solution
Engineering NK cells derived from hPSCs to overexpress ID2, NFIL3, and/or SPI1, and equipping them with anti-PD-L1 and anti-FITC chimeric antigen receptors (CARs) to enhance tumor recognition and persistence, using a CRISPR/Cas9-mediated gene knock-in technique.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional NK cell production methods from hPSCs are used, then NK cells can be generated, but the protocols are non-standardized and have low reproducibility
Solution Approach 1:
The patent changes the key parameter of differentiation protocol by specifying precise culture conditions including defined media composition, cytokine concentrations, and differentiation timepoints. This standardization of parameters enables reproducible NK cell generation from hPSCs across different batches and laboratories.
Solution Approach 2:
The differentiation process is segmented into distinct stages with specific protocols for each phase: hPSC maintenance, early differentiation, NK cell commitment, and maturation. Each stage has defined criteria and control points, enabling standardized production and quality control.
2Ease of manufacture
If current hPSC-based NK cell production protocols are used, then NK cells can be produced, but the process is expensive due to expensive growth factors and animal-derived components
Solution Approach 1:
The patent replaces expensive, animal-derived growth factors and serum components with affordable, recombinant human cytokines and defined media components. This substitution reduces material costs while maintaining cell quality, enabling scalable production at clinically relevant dosages.
Solution Approach 2:
The protocol optimizes cytokine dosing parameters and culture time parameters to reduce overall consumption of expensive reagents while maintaining efficient NK cell expansion, thereby reducing production costs.
3Productivity
If traditional differentiation protocols are used, then NK cells can be derived from hPSCs, but the derivation period is long (seven or more weeks)
Solution Approach 1:
The patent applies preliminary genetic modification of hPSCs to overexpress ID2, NFIL3, and SPI1 transcription factors before differentiation. This preliminary action primes the cells for rapid NK cell commitment, significantly shortening the derivation period from seven+ weeks to a more efficient timeline.
Solution Approach 2:
The differentiation time parameters are optimized and compressed by changing culture conditions and cytokine timing, reducing the overall derivation period while maintaining NK cell quality and yield.
4Reliability
If conventional NK cell therapy is used, then tumor cells can be attacked, but immunological memory is limited and cell exhaustion occurs
Solution Approach 1:
The patent performs preliminary genetic engineering of hPSCs to overexpress transcription factors ID2, NFIL3, and SPI1 that are critical for generating NK cells with enhanced memory-like phenotypes. This preliminary action ensures that the resulting NK cells possess improved persistence and reduced exhaustion before they are even differentiated.
Solution Approach 2:
The patent creates composite engineered NK cells that combine multiple genetic modifications (transcription factor overexpression lines, CAR expressions) to produce cells with both potent immediate anti-tumor activity and enhanced long-term memory characteristics, merging the benefits of different cellular properties.
5Manufacturing precision
If NK cells are engineered with CARs for tumor targeting, then tumor recognition is improved, but the complexity of cell engineering increases
Solution Approach 1:
The patent segments the engineering process into modular components: transcription factor overexpression modules, CAR expression modules, and safety switch modules. Each module can be independently designed, tested, and combined, reducing overall complexity while achieving multiple functions.
Solution Approach 2:
The patent develops universal hPSC-derived NK cell platforms that can be engineered with different CAR specificities using the same base protocol and transcription factor overexpression system. This universal platform reduces engineering complexity by reusing proven components across different tumor targets.
Data Source
AI summary
A population of universal natural killer (NK) cells derived from human pluripotent stem cells (hPSCs) and engineered to overexpress the transcription factor ID2, NFIL3, and/or SPI1 and, optionally, an anti-programmed death ligand 1 (PD-L1) chimeric antigen receptor (CAR) and an anti-fluorescein isothiocyanate CAR are provided. Methods of treating cancer in a subject using the population of universal NK cells are also provided.